1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
JCR, Takeda End Global Collab for Hunter Syndrome Therapy
JCR Pharmaceuticals said on June 25 that it has regained all licenses and commercialization rights to its Hunter syndrome drug JR-141 (pabinafusp alfa) from Takeda Pharmaceutical as they have agreed to end their collaboration for the product. The termination of…
To read the full story
Related Article
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- JCR, Takeda Seal R&D Pact on Gene Therapies Using BBB Technology
March 29, 2022
- JCR’s Hunter Syndrome Drug Earns PRIME Tag in Europe
October 19, 2021
- Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
- JCR Hooks Up with Takeda on Global Expansion of Hunter Syndrome Drug
October 1, 2021
BUSINESS
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Darzquro Filed for High-Risk Smoldering MM in Japan: J&J
February 17, 2025
- Nxera Founder Tamura to Bow Out from Board
February 17, 2025
- Kerendia Filed for Chronic Heart Failure in Japan: Bayer
February 17, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…